Two Partial Agonists, Different Selectivity Profiles
Both MK-2866 (Ostarine) and Andarine (S4) are partial agonists at the androgen receptor, but they occupy meaningfully different positions in the SARM research landscape. Ostarine is characterized by high tissue selectivity and a large accumulated human safety dataset. Andarine, developed earlier, offers a higher binding affinity but with a unique off-target effect — partial agonism at the androgen receptor in the eye — that has made it a subject of interest in vision research and a cautionary example in SARM selectivity studies.
The Vision Effect: S4’s Unique Research Variable
Andarine’s most-discussed characteristic is the transient visual disturbance it causes in human subjects — specifically a yellowish tint to vision and difficulty adapting to low-light environments. This effect, observed at doses above 50 mg/day, arises from partial agonism at the androgen receptor in the retina and lens. For researchers studying AR expression in ocular tissue, S4 represents a unique tool compound. In studies not focused on ocular endpoints, this effect is typically listed as a confounding variable and managed through dose reduction or study exclusion criteria.
Comparative Muscle and Bone Research Applications
For musculoskeletal endpoints, both compounds produce dose-dependent increases in lean body mass in animal models. Andarine’s higher binding affinity theoretically produces a stronger anabolic signal per unit dose, but the added complexity of the visual side effect and a shorter half-life (requiring multiple daily doses in animal studies) have led most researchers to prefer Ostarine as their primary SARM when these endpoints are being studied. Ostarine’s milder HPG axis suppression is also valued in longer-duration studies.
Where Andarine Remains Relevant
S4 retains relevance in foundational AR pharmacology work, dose-response characterization in bone tissue, and studies specifically designed to probe receptor selectivity differences across tissue types. It also frequently appears in SARM panel studies alongside RAD-140, LGD-4033, and Ostarine for comprehensive receptor profiling.
Available Research Products
- MK-2866 Ostarine Solution (25mg/ml – 50ml)
- Andarine S4 Solution (50mg/ml – 50ml) | Andarine S4 Powder (1g)
See our full guide: MK-2866 Ostarine Research Guide. For laboratory research use only.
